P137Lack of effect of remote ischemic perconditioning in rats with type 1 diabetes in vivo

    loading  Checking for direct PDF access through Ovid


Aims: It is well established that preconditioning effectively protects from myocardial ischemia-reperfusion (IR) injury. It has been suggested that co-morbidities including diabetes may impair the cardioprotective effect of preconditioning. More recently also remote ischemic perconditioning (RIPerc), which is a clinically more feasible mode of cardioprotective treatment, has been shown to reduce infarct size. It is not known, however, whether RIPerc is affected by co-morbidities. The objective of this study was to investigate whether signaling mechanisms and the cardioprotective effect of RIPerc are influenced by presence of diabetes.

Methods: The study was performed on non-diabetic and diabetic Sprague-Dawley rats. Diabetes was induced by streptozotocin (55 mg/kg iv) given 4 weeks before IR experiments. The rats were subjected to 30 min left coronary artery ligation followed by 2 h reperfusion with or without RIPerc induced by bilateral femoral artery occlusion for 15 min during the last 15 min of coronary artery occlusion (n=6-7 in all groups).

Results: RIPerc reduced infarct size (expressed in percentage of the area at risk) in non-diabetic rats from 68±2% to 46±4% (P<0.001). This effect was associated with increased expression of phosphorylated (ser 1177) eNOS expression and reduced activity of Rho kinase and arginase. Infarct size in rats with type 1 diabetes subjected to IR was 68±1%. In contrast to control rats, RIPerc did not affect infarct size in type 1 diabetic rats (infarct size 63±2%). Furthermore, expression of phosphorylated eNOS, Rho kinase activity and arginase activity was unaffected by RIPerc in diabetic rats.

Conclusion: RIPerc fails to protect from myocardial IR injury in rats with type 1 diabetes. Furthermore, upstream signaling events contributing to the cardioprotection induced by RIPerc are unaffected in diabetic rats. This finding may have important implications for the efficacy of cardioprotective treatment in diabetes.

Related Topics

    loading  Loading Related Articles